Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Ozanimod for treating relapsing–remitting multiple sclerosis ID1294

Final Stakeholder list

Consultees	**Commentators (no right to submit or appeal)**
Company(ies) • Celgene (ozanimod) Patient/carer groups • Multiple Sclerosis Society • Multiple Sclerosis Trust Professional groups • Association of British Neurologists • Royal College of Physicians • UK Multiple Sclerosis Specialist Nurse Association Others • Department of Health • NHS England • Welsh Government	General • All Wales Therapeutics and Toxicology Centre • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Comparator companies • Bayer (interferon beta-1b) (confidentiality agreement not signed, not participating) • Biogen Idec (dimethyl fumarate, interferon beta-1a, natalizumab, peginterferon beta-1a) • Genzyme Therapeutics (alemtuzumab, teriflunomide) (confidentiality agreement not signed, not participating) • Merck Serono (cladribine tablets, interferon beta-1a) (confidentiality agreement not signed, not participating) • Novartis (fingolimod, interferon beta-1b) • Teva UK (glatiramer acetate) (confidentiality agreement not signed, not participating) • Roche (ocrelizumab) • Janssen (ponesimod)

Appendix C

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

[1]Non-company consultees are invited to submit statements relevant to the group they are representing.